Journal of Clinical Endocrinology & Metabolism, Vol 74, 593-599, Copyright © 1992 by Endocrine Society

ARTICLES

Defective ring A reduction of cortisol as the major metabolic error in the syndrome of apparent mineralocorticoid excess

S Ulick, R Tedde and JZ Wang
Veterans Affairs Hospital, Bronx, New York 10468.

Impaired peripheral metabolism of cortisol in the syndrome of apparent mineralocorticoid excess is currently understood to be causally related to the severe but otherwise unexplained manifestations of mineralocorticoid excess. A normally ambivalent mineralocorticoid receptor responding equally well to glucocorticoids and mineralocorticoids requires prereceptor inactivation of glucocorticoids to elicit a specific mineralocorticoid effect. The failed inactivation step in the form of the syndrome of apparent mineralocorticoid excess first described (type 1) involves the 11 beta-hydroxydehydrogenation of cortisol to cortisone. In another form of the syndrome (type 2) this conversion occurs normally in the face of otherwise similar clinical and biochemical features. Markedly decreased cortisol metabolic clearance in the type 2 form suggested impairment of a major component of that clearance, ring A reduction. A noninvasive method was developed for measuring the conversion of cortisol to tetrahydrocortisol and allotetrahydrocortisol, and this step was found to be profoundly decreased in both type 1 and type 2 forms. Thus, the major abnormality in the peripheral metabolism of cortisol common to both forms involved ring A reduction, not 11 beta-hydroxydehydrogenation. Since ring A reduction was better correlated with the manifestation of mineralocorticoid excess in both forms of the syndrome, this step might also be a normal major prereceptor mechanism conferring mineralocorticoid specificity.

This article has been cited by other articles:

				S. Wiegand, A. Richardt, T. Remer, S. A Wudy, J. W Tomlinson, B. Hughes, A. Gruters, P. M Stewart, C. J Strasburger, and M. Quinkler Reduced 11{beta}-hydroxysteroid dehydrogenase type 1 activity in obese boys Eur. J. Endocrinol., September 1, 2007; 157(3): 319 - 324. [Abstract] [Full Text] [PDF]

				J. Westerbacka, H. Yki-Jarvinen, S. Vehkavaara, A.-M. Hakkinen, R. Andrew, D. J. Wake, J. R. Seckl, and B. R. Walker Body Fat Distribution and Cortisol Metabolism in Healthy Men: Enhanced 5{beta}-Reductase and Lower Cortisol/Cortisone Metabolite Ratios in Men with Fatty Liver J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4924 - 4931. [Abstract] [Full Text] [PDF]

				R. C. Andrews, O. Herlihy, D. E. W. Livingstone, R. Andrew, and B. R. Walker Abnormal Cortisol Metabolism and Tissue Sensitivity to Cortisol in Patients with Glucose Intolerance J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5587 - 5593. [Abstract] [Full Text] [PDF]

				P. Heilmann, E. Buchheim, J. Wacker, and R. Ziegler Alteration of the Activity of the 11{beta}-Hydroxysteroid Dehydrogenase in Pregnancy: Relevance for the Development of Pregnancy-Induced Hypertension? J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5222 - 5226. [Abstract] [Full Text] [PDF]

				A. Jamieson, A. M. Wallace, R. Andrew, B. S. Nunez, B. R. Walker, R. Fraser, P. C. White, and J. M. C. Connell Apparent Cortisone Reductase Deficiency: A Functional Defect in 11{beta}-Hydroxysteroid Dehydrogenase Type 1 J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3570 - 3574. [Abstract] [Full Text] [PDF]

				M. J. J. Finken, R. C. Andrews, R. Andrew, and B. R. Walker Cortisol Metabolism in Healthy Young Adults: Sexual Dimorphism in Activities of A-Ring Reductases, but not 11{beta}-Hydroxysteroid Dehydrogenases J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3316 - 3321. [Abstract] [Full Text]

				G. Morineau, J.-M. Marc, A. Boudi, H. Galons, M. Gourmelen, P. Corvol, L. Pascoe, and J. Fiet Genetic, Biochemical, and Clinical Studies of Patients With A328V or R213C Mutations in 11{beta}HSD2 Causing Apparent Mineralocorticoid Excess Hypertension, September 1, 1999; 34(3): 435 - 441. [Abstract] [Full Text] [PDF]

				M. Panarelli, C. D. Holloway, R. Fraser, J. M. C. Connell, M. C. Ingram, N. H. Anderson, and C. J. Kenyon Glucocorticoid Receptor Polymorphism, Skin Vasoconstriction, and Other Metabolic Intermediate Phenotypes in Normal Human Subjects J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1846 - 1852. [Abstract] [Full Text]

				S. H.M. van Uum, A. R.M.M. Hermus, P. Smits, T. Thien, and J. W.M. Lenders The role of 11{beta}-hydroxysteroid dehydrogenase in the pathogenesis of hypertension Cardiovasc Res, April 1, 1998; 38(1): 16 - 24. [Abstract] [Full Text] [PDF]

				P. C. White, T. Mune, and A. K. Agarwal 11{beta}-Hydroxysteroid Dehydrogenase and the Syndrome of Apparent Mineralocorticoid Excess Endocr. Rev., February 1, 1997; 18(1): 135 - 156. [Abstract] [Full Text]

				H. Shibata, H. Suzuki, T. Maruyama, and T. Saruta Gene Expression of Angiotensin II Receptor in Blood Cells of Cushing's Syndrome Hypertension, December 1, 1995; 26(6): 1003 - 1010. [Abstract] [Full Text]

				A. Soro, M. C. Ingram, G. Tonolo, N. Glorioso, and R. Fraser Evidence of Coexisting Changes in 11ß-Hydroxysteroid Dehydrogenase and 5ß-Reductase Activity in Subjects With Untreated Essential Hypertension Hypertension, January 1, 1995; 25(1): 67 - 70. [Abstract] [Full Text]

				P. C. White Disorders of Aldosterone Biosynthesis and Action N. Engl. J. Med., July 28, 1994; 331(4): 250 - 258. [Full Text]